Viriom

MD - RockvilleBiotechnology

Website LinkedIn Careers Page

Focus: Infectious Diseases

Viriom is a life sciences company focused on Infectious Diseases.

Infectious Diseases

Profile data last refreshed Yesterday

Open Jobs

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Elpida® + 2 NRTIs

HIV-1-infection

N/A

Clinical Trials (1)

NCT03706950Post-approval Observational Study of Elpida® in the First Line Therapy for HIV-1 Infected Patients With Background Standard ART

N/A

Help build intelligence for Viriom

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

VM-1500

HIV-infection

Phase 1

Clinical Trials (1)

NCT02489487Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500

Phase 1

Elpida

HIV Infections

Phase 1

Clinical Trials (1)

NCT05204121Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

Phase 1

VM-1500

HIV-infection

Phase 1

Clinical Trials (1)

NCT02489435Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers

Phase 1

Elpida

HIV Infections

Phase 1

Clinical Trials (1)

NCT03730311Phase Ib Study of Safety, Tolerability and Pharmacokinetics of Elpida Once Weekly in Healthy Volunteers

Phase 1

Elsulfavirine

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT05165550Study of Single Ascending Doses of Elsulfavirine to Evaluate the Safety, Tolerability, and Pharmacokinetics of Elsulfavirine and Its Active Metabolite VM-1500A in Healthy Subjects

Phase 1

Elpida®

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT03706898Study to Evaluate the Safety and PK of Elpida® in Healthy Subjects and Patients With Hepatic Impairment and to Assess the Impact of Food Intake and Drug-Drug Interactions With Other Antiviral Drugs

Phase 1

VM-1500FDC

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT03706924Comparative Study of PK and BE of VM-1500FDC (Fixed-dose Combination) and Elpida® With Truvada® сo-administrated 1 Daily Fasting in Healthy Subjects

Phase 1

VM-1500A-LAI

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT03706911Study to Evaluate Safety, Tolerability and Pharmacokinetics of VM-1500A-LAI Single and Multiple Ascending Doses in Healthy Subjects

Phase 1

Elsulfavirine

Covid19

Phase 1

Clinical Trials (1)

NCT05148754An Open-label Clinical Study of the Pharmacokinetics and Safety of Elsulfavirine, 200 mg Tablets, With Single and Multiple Oral Administration in Healthy Volunteers

Phase 1

Elpida®

HIV-1-infection

Phase 1

Clinical Trials (1)

NCT03709355Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs

Phase 1

VM-1500/Placebo

HIV Infection

Phase 1/2

Clinical Trials (1)

NCT02485509Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection

Phase 1/2

VM-1500A-LAI

HIV-1-infection

Phase 1/2

Clinical Trials (1)

NCT05163535Open Labelled, Randomized Study to Evaluate the Efficacy, Safety and Dose Selection of VM-1500A-LAI Drug in HIV-infected Patients Transferred From Previous Stable Therapy (NNRTI + 2NRTI), Including ELPIDA®

Phase 1/2

Quisinostat

Uveal Melanoma

Phase 2

Clinical Trials (1)

NCT06932757Adjuvant Quisinostat in High-Risk Uveal Melanoma

Phase 2

AV5080

Influenza

Phase 2

Clinical Trials (1)

NCT05095545Dose Range Study to Evaluate the Efficacy and Safety of AV5080 in Patients With Influenza